Moderna's vaccine is 100% effective in adolescents

Although we recently talked to you about how Moderna was going to request permission from the European Medicines Agency to be able to supply its vaccine in adolescents, we now receive data from the results of its tests in young people between 12 and 18 years old with proven effectiveness. Moderna vaccine is 100% effective in adolescents 12 to 18 years old No case of Covid: This is the result of testing of Moderna vaccine in adolescents. But one dose is not enough, but two. Because only after the double injection was the American drug 100% effective, while after the first dose it was 93%. The data was released by Moderna and is related to the TeenCOVE study on youth. “We are motivated by the fact that mRNA has been highly effective in preventing Covid-19 in adolescents,” said Stéphane Bancel, CEO of Moderna. We will send these results to the FDA and other regulatory bodies in early June, requesting authorization. ”Efficacy and side effects According to the study conducted by Moderna to determine the effectiveness of its vaccines in adolescents, there were no cases of Covid after both were administered. doses, compared to 4 reported in the placebo group. And therefore, the vaccine is 100% effective from 14 days after the second injection. But what about the side effects? Most of the adverse events were mild or moderate in severity, the pharmacist reports. The most frequent were pain at the injection site and after the second dose headache, fatigue, myalgia and chills. The company explains that safety data continues to accumulate and the study continues to be monitored by an independent committee.All participants will be followed for 12 months after their second injection, with the aim of evaluating the long-term protection and safety of the vaccine. Age range and safety The tests were conducted among children between 12 and 18 years of age. And “no major security issues were found.” This is announced by the US pharmaceutical company when it communicates that the phase 2/3 study of its TeenCOVE vaccine (mRNA-1273) for adolescents reaches the primary endpoint of immunogenicity not inferior to that of the adult comparison group. for Disease Control and Prevention (Cdc), a 93% vaccine efficacy was observed after the first dose. After the two doses, they insist that no cases of Covid-19 were observed. And this result is consistent with a 100% vaccine efficacy. The TeenCOVE study recruited more than 3,700 participants ages 12 to 18 in the United States.